ArticleDiscover oncology2025
Identification and validation of cholesterol metabolism-related gene GNB3 as prognosis biomarker for pancreatic adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Patients with pancreatic cancer have a poor prognosis. The role of cholesterol metabolism-related genes (CMGs) pattern in pancreatic adenocarcinoma (PAAD) clinical prognostic significance is still unsuspected. In this study, 13 CMGs were eventually chosen as the prognostic signature to construct a risk model in PAAD. GNB3 as an independent prognosis factor linked to CMGs was ultimately found in PAAD. Kaplan-Meier (KM) and area under the curve (AUC) analysis indicated that the overall survival (OS) for GNB3 in the low-risk group was higher than that of PAAD patients compared with those in the high-risk group. Radiotherapy can significantly increase the GNB3 expression and the survival time in PAAD. GNB3 was differentially expressed and significantly associated with survival prognosis, immune checkpoints, and immune-infiltrating cells in pan-cancer. Specifically, survival analysis further identified that GNB3 was significantly associated with OS, progression-free survival, disease-free survival, and disease-specific survival in PAAD. The IHC scores indicated that the protein expression of GNB3 was lower in tumor tissues. The current study offers fresh insights into the possibility of GNB3 associated with CMGs as new biomarkers for the clinical diagnosis and prognostic for PAAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.